Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 7/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30634808 | 1.00 | HTT (0.34) | HTTMAPTLMNAARHCRTR1 | |
| SCHEMBL30634790 | 0.88 | PIK3CD (0.38) | — | |
| SCHEMBL26670649 | 0.84 | HCRTR2 (0.42) | ARHCRTR1HCRTR2 | |
| SCHEMBL26670726 | 0.78 | AR (0.38) | ARHCRTR1HCRTR2 | |
| SCHEMBL26670647 | 0.77 | HCRTR1 (0.41) | ARHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL26670654 | 0.77 | HCRTR1 (0.41) | ARHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL26670745 | 0.74 | AR (0.36) | ARHCRTR1HCRTR2 | |
| SCHEMBL30101679 | 0.72 | CACNB4 (0.38) | MAPTLMNAPOLB | |
| SCHEMBL31507307 | 0.71 | PIK3CD (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL30634805 | 0.71 | PIK3CD (0.41) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023230477-A1 | PYRIDINE CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2023-11-30 | — | — | WO | disclosed |